These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38130122)

  • 1. Features of immunometabolic depression as predictors of antidepressant treatment outcomes: pooled analysis of four clinical trials.
    Vreijling SR; Chin Fatt CR; Williams LM; Schatzberg AF; Usherwood T; Nemeroff CB; Rush AJ; Uher R; Aitchison KJ; Köhler-Forsberg O; Rietschel M; Trivedi MH; Jha MK; Penninx BWJH; Beekman ATF; Jansen R; Lamers F
    Br J Psychiatry; 2024 Mar; 224(3):89-97. PubMed ID: 38130122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antidepressants for people with epilepsy and depression.
    Maguire MJ; Marson AG; Nevitt SJ
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD010682. PubMed ID: 33860531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidepressants for people with epilepsy and depression.
    Maguire MJ; Weston J; Singh J; Marson AG
    Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010682. PubMed ID: 25464360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.
    Kessler D; Burns A; Tallon D; Lewis G; MacNeill S; Round J; Hollingworth W; Chew-Graham C; Anderson I; Campbell J; Dickens C; Macleod U; Gilbody S; Davies S; Peters TJ; Wiles N
    Health Technol Assess; 2018 Nov; 22(63):1-136. PubMed ID: 30468145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vortioxetine for depression in adults.
    Koesters M; Ostuzzi G; Guaiana G; Breilmann J; Barbui C
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011520. PubMed ID: 28677828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of immuno-metabolic depression features in the effects of light therapy in patients with depression and type 2 diabetes mellitus: A randomized controlled trial.
    Vreijling SR; Neuhaus L; Brouwer A; Penninx BWJH; Beekman ATF; Lamers F; Jansen R; Bremmer M
    J Psychosom Res; 2024 Jun; 181():111671. PubMed ID: 38657564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease.
    Pollok J; van Agteren JE; Carson-Chahhoud KV
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012346. PubMed ID: 30566235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial.
    Salaminios G; Duffy L; Ades A; Araya R; Button KS; Churchill R; Croudace T; Derrick C; Dixon P; Dowrick C; Gilbody S; Hollingworth W; Jones V; Kendrick T; Kessler D; Kounali D; Lanham P; Malpass A; Peters TJ; Riozzie D; Robinson J; Sharp D; Thomas L; Welton NJ; Wiles N; Lewis G
    Trials; 2017 Oct; 18(1):496. PubMed ID: 29065916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidepressant treatment for postnatal depression.
    Brown JVE; Wilson CA; Ayre K; Robertson L; South E; Molyneaux E; Trevillion K; Howard LM; Khalifeh H
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013560. PubMed ID: 33580709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity.
    Jha MK; Minhajuddin A; South C; Rush AJ; Trivedi MH
    Am J Psychiatry; 2019 May; 176(5):358-366. PubMed ID: 30922100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
    Fourrier C; Sampson E; Mills NT; Baune BT
    Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial.
    Friedman ES; Davis LL; Zisook S; Wisniewski SR; Trivedi MH; Fava M; Rush AJ;
    Eur Neuropsychopharmacol; 2012 Mar; 22(3):183-99. PubMed ID: 21920711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein.
    O'Connell CP; Goldstein-Piekarski AN; Nemeroff CB; Schatzberg AF; Debattista C; Carrillo-Roa T; Binder EB; Dunlop BW; Craighead WE; Mayberg HS; Williams LM
    Am J Psychiatry; 2018 Mar; 175(3):251-261. PubMed ID: 29241359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S-adenosyl methionine (SAMe) for depression in adults.
    Galizia I; Oldani L; Macritchie K; Amari E; Dougall D; Jones TN; Lam RW; Massei GJ; Yatham LN; Young AH
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD011286. PubMed ID: 27727432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of antidepressant drugs in schizophrenic patients with depression].
    Micallef J; Fakra E; Blin O
    Encephale; 2006; 32(2 Pt 1):263-9. PubMed ID: 16910628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach.
    Chekroud AM; Gueorguieva R; Krumholz HM; Trivedi MH; Krystal JH; McCarthy G
    JAMA Psychiatry; 2017 Apr; 74(4):370-378. PubMed ID: 28241180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a Machine Learning Model Based on Pretreatment Symptoms and Electroencephalographic Features to Predict Outcomes of Antidepressant Treatment in Adults With Depression: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Rajpurkar P; Yang J; Dass N; Vale V; Keller AS; Irvin J; Taylor Z; Basu S; Ng A; Williams LM
    JAMA Netw Open; 2020 Jun; 3(6):e206653. PubMed ID: 32568399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.
    Bobo WV; Chen H; Trivedi MH; Stewart JW; Nierenberg AA; Fava M; Kurian BT; Warden D; Morris DW; Luther JF; Husain MM; Cook IA; Lesser IM; Kornstein SG; Wisniewski SR; Rush AJ; Shelton RC
    J Affect Disord; 2011 Oct; 133(3):467-76. PubMed ID: 21601287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dimensions of anxiety in Major depressive disorder and their use in predicting antidepressant treatment outcome: an iSPOT-D report.
    Braund TA; Palmer DM; Williams LM; Harris AWF
    Psychol Med; 2020 Apr; 50(6):1032-1042. PubMed ID: 31023398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.